Pigment epithelium-derived factor as an anticancer drug and new treatment methods following the discovery of its receptors: a patent perspective

Pigment epithelium-derived factor binds to cell-surface F1-ATP synthase

(2010) Luigi Notari et al.   FEBS Journal

A chitosan–dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma

(2009) Hang T. Ta et al.   BIOMATERIALS

Pigment Epithelium-Derived Factor Contributes to Insulin Resistance in Obesity

(2009) Seamus Crowe et al.   Cell Metabolism

In vitroandin vivobiological activity of PEDF against a range of tumors

(2009) Matthew L Broadhead et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Laminin Receptor Involvement in the Anti-angiogenic Activity of Pigment Epithelium-derived Factor

(2009) Adrien Bernard et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The anti-angiogenic factor PEDF is present in the human heart and is regulated by anoxia in cardiac myocytes and fibroblasts

(2009) Kathrin Rychli et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Characterization of PEDF: A multi-functional serpin family protein

(2009) S. Filleur et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Cancer cell apoptotic pathways mediated by PEDF: prospects for therapy

(2009) Matthew L. Broadhead et al.   TRENDS IN MOLECULAR MEDICINE

PEDF as an Emerging Therapeutic Candidate for Osteosarcoma

(2008) Crispin Dass et al.   CURRENT CANCER DRUG TARGETS

Anti-angiogenic pigment epithelium-derived factor regulates hepatocyte triglyceride content through adipose triglyceride lipase (ATGL)

(2008) Chuhan Chung et al.   JOURNAL OF HEPATOLOGY